GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...
By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.
SINGAPORE, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FAST TRACK GROUP (NASDAQ: FTRK) (“Fast Track” or the “Company”), a leading entertainment-focused event management and celebrity agency company, announced ...
The Louisiana Public Service Commission on Wednesday voted to fast-track Entergy’s proposal to power Meta’s data center in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results